Takeda has announced that the National Institute for Health and Care Excellence (NICE) has recommended Ninlaro with lenalidomide and dexamethasone.
Takeda’s ongoing bid to expand the audience for its cancer drug Ninlaro has suffered some setbacks this year, but now the company can claim one big win—and investors are cheering.
Five months after dismal trial results convinced Takeda to scrap an entire Phase III program for their multiple myeloma drug Ninlaro, the Japanese giant announced a different late-stage trial has met its primary endpoint — although they have yet to release any data.
In the wake of its $64 billion buyout of Shire early last year, Takeda Pharmaceuticals outlined an ambitious consolidation of its operations in the Boston area. For the drugmaker’s 1,000 employees in the Chicago suburbs, that planned move now has a deadline.
With its once-biggest seller Velcade bracing for generic competition, Takeda has big plans for its oral multiple myeloma drug Ninlaro. But now, the med has suffered two setbacks in the span of a few months. After Ninlaro hit a snag at the FDA in an expanded use back in February, the company this week canned a phase 3 trial in another rare disease.
Takeda has stumbled again in its quest to build up the blockbuster potential of its multiple myeloma drug Ninlaro. The pharma giant says the drug combined with dexamethasone failed to provide significant help for patients with rare cases of systemic light-chain amyloidosis, so now they’re scrapping the entire Phase III program.
Right now, the first infusion of Johnson & Johnson multiple myeloma fighter Darzalex can take between seven and eight hours. But data on a new formulation could be a game changer. At the American Society of Clinical Oncology annual meeting, the New Jersey drugmaker trumpeted results from a phase 3 study showing that a subcutaneous form of Darzalex could measure up to the original—and with an average injection time of just five minutes.
Takeda's Ninlaro (ixazomib citrate) Receives Conditional approval in Europe
NICE has stuck to its decision not to recommend Takeda's multiple myeloma therapy Ninlaro for routine use in the NHS in England and Wales after a consultation process.
n eye for an eye, a tooth for a tooth — a life for a lab book?nnIn the past few months, China has announced two new crackdowns on research misconduct — one of which could lead to executions for scientists who doctor their data.